Ethyl Linoleate
CAS 544-35-4
Ethyl Linoleate (CAS 544-35-4) is a Phase 1 pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 22874.1 nM | 2 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ETHYL LINOLEATE | 24522 | SU | MTHSPL |
| ethyl linoleate | 24522 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ethyl Linoleate used for in pharmaceutical contexts?
Ethyl Linoleate (CAS 544-35-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ethyl Linoleate?
No adverse-event association or SIDER side-effect rows are rendered for Ethyl Linoleate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ethyl Linoleate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Ethyl Linoleate with EU status "permitted".
What clinical phase is Ethyl Linoleate in?
Ethyl Linoleate is rendered with ChEMBL max phase 1.